Published Online
on March 8, 2007

A more recent version of this article appeared on April 1, 2007

This Article Full Text (PDF) All Versions of this Article: 38/4/1396    most recent 01.STR.0000260101.08944.e9v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hachinski, V. Search for Related Content PubMed PubMed Citation Articles by Hachinski, V. Related Collections Other Stroke Treatment - Medical

Submitted on December 13, 2006
Revised on January 24, 2007
Accepted on January 31, 2007

The 2005 Thomas Willis Lecture. Stroke and Vascular Cognitive Impairment. A Transdisciplinary, Translational and Transactional Approach

Vladimir Hachinski MD, FRCPC, DSc^*

From the University of Western Ontario, London, Canada.

^* To whom correspondence should be addressed. E-mail: stroke{at}lhsc.on.ca.

Abstract--Advances in stroke are occurring at an unprecedented pace, but often in disciplinary isolation and without optimal mechanisms for systematically translating, integrating and applying the findings.

Knowledge accrues in pieces, but is understood in patterns. To optimize knowledge acquisition and application, infrastructures and systems need to be set up along with appealing incentives. The approach needs to be transdisciplinary, going beyond the bounds of any given discipline, reciprocally translational, and transactional, meaning that the interchanges have to yield previously agreed benefits to the parties (The Triple T Approach). A new breed of leaders needs to be developed and nurtured to catalyze the process.

Opportunities abound. Stroke and most brain diseases share the same pathophysiological fundamental mechanisms. An integrated, systematic approach to these processes could yield not only greater understanding but new, common therapeutic targets for several diseases. Biphasic clinical trials could combine the best features of pragmatic and explanatory, randomized clinical trials. The greatest opportunity of all may be the largely under-explored and under-exploited borderlands between cerebrovascular and Alzheimer disease. One in three of us will have a stroke, become demented, or both. For each person who has a stroke or Alzheimer disease, two have some cognitive impairment short of dementia, often subclinical cerebrovascular disease on a substrate of Alzheimer changes. The fact that cerebrovascular and Alzheimer disease share the same risk factors, provide a great opportunity for prevention, if implemented at the "brain at risk" stage.

Systematically integrating what we know and evaluating what we do could spur progress. Research is not only an activity but an attitude. Making evaluation and incentives to excel part of the funding of all stroke activities would yield far ranging cumulative improvements in all aspects of stroke.

No system can replace the individual initiative, creativity and insights that lead to the great discoveries, but progress is not made by breakthroughs alone. No one’s work is so exalted that it cannot be improved, nor so humble that it has no value. We can all make a difference.

Key words: Alzheimer disease • clinical trials • discovery • intervention • stroke • treatment • vascular cognitive impairment

This article has been cited by other articles:

				V. Hachinski World Stroke Day 2009: What Can I Do? Stroke, October 1, 2009; 40(10): 3165 - 3165. [Full Text] [PDF]

				D. J Llewellyn, I. A Lang, K. M Langa, F. Naughton, and F. E Matthews Exposure to secondhand smoke and cognitive impairment in non-smokers: national cross sectional study with cotinine measurement BMJ, February 12, 2009; 338(feb12_2): b462 - b462. [Abstract] [Full Text] [PDF]

				J. M. Wardlaw What Is a Lacune? Stroke, November 1, 2008; 39(11): 2921 - 2922. [Full Text] [PDF]

				V. Hachinski World Stroke Day 2008: "Little Strokes, Big Trouble" Stroke, September 1, 2008; 39(9): 2407 - 2408. [Full Text] [PDF]

				R. H. Swartz, D. T. Stuss, F. Gao, and S. E. Black Independent Cognitive Effects of Atrophy and Diffuse Subcortical and Thalamico-Cortical Cerebrovascular Disease in Dementia Stroke, March 1, 2008; 39(3): 822 - 830. [Abstract] [Full Text] [PDF]

				P. B. Gorelick and J. V. Bowler Advances in Vascular Cognitive Impairment 2007 Stroke, February 1, 2008; 39(2): 279 - 282. [Full Text] [PDF]

				H. Aleyasin, M. W. C. Rousseaux, M. Phillips, R. H. Kim, R. J. Bland, S. Callaghan, R. S. Slack, M. J. During, T. W. Mak, and D. S. Park The Parkinson's disease gene DJ-1 is also a key regulator of stroke-induced damage PNAS, November 20, 2007; 104(47): 18748 - 18753. [Abstract] [Full Text] [PDF]

				R. L. Sacco The 2006 William Feinberg Lecture: Shifting the Paradigm From Stroke to Global Vascular Risk Estimation Stroke, June 1, 2007; 38(6): 1980 - 1987. [Abstract] [Full Text] [PDF]